Rein Therapeutics (RNTX) Total Current Liabilities (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Total Current Liabilities of $13.6 million for Q1 2026, up 128.16% year-over-year from $6.0 million in Q1 2025, and up 120.66% quarter-over-quarter from $6.2 million in Q4 2025.
Rein Therapeutics (RNTX) Total Current Liabilities (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Total Current Liabilities for 11 consecutive years, with $13.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 128.16% year-over-year to $13.6 million; the TTM figure through Mar 2026 stood at $13.6 million (up 128.16% YoY), while the FY2025 annual figure was $6.2 million, up 7.5% from the prior year.
- Total Current Liabilities grew to $13.6 million in Q1 2026 per RNTX's latest filing, from $6.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $13.6 million in Q1 2026 and bottomed at $1.2 million in Q2 2023.
- Historically, Total Current Liabilities has averaged $5.1 million across 5 years, with a median of $4.9 million in 2024.
- Annual changes were most pronounced in 2023 — Total Current Liabilities tumbled 76.76% — and 2024, when it soared 312.45%.
- Rein Therapeutics' Total Current Liabilities stood at $3.4 million in 2022, then gained by 29.58% to $4.4 million in 2023, then soared by 31.11% to $5.7 million in 2024, then grew by 7.5% to $6.2 million in 2025, then jumped by 120.66% to $13.6 million in 2026.
- Business Quant data shows RNTX's Total Current Liabilities at $13.6 million in Q1 2026, $6.2 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 630.93 Mn |
| 10 | Rein Therapeutics | 53.61 Mn | 53.61 Mn | - | 9.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.71 Mn |
| Mar 31, 2026 | 13.64 Mn |
| Dec 31, 2025 | 6.18 Mn |
| Sep 30, 2025 | 5.74 Mn |
| Jun 30, 2025 | 7.69 Mn |
| Mar 31, 2025 | 5.98 Mn |
| Dec 31, 2024 | 5.75 Mn |
| Sep 30, 2024 | 5.66 Mn |
| Jun 30, 2024 | 4.94 Mn |
| Mar 31, 2024 | 4.53 Mn |
| Dec 31, 2023 | 4.39 Mn |
| Sep 30, 2023 | 1.62 Mn |
| Jun 30, 2023 | 1.20 Mn |
| Mar 31, 2023 | 2.88 Mn |
| Dec 31, 2022 | 3.38 Mn |
| Sep 30, 2022 | 4.54 Mn |
| Jun 30, 2022 | 5.15 Mn |
| Mar 31, 2022 | 4.15 Mn |
| Dec 31, 2021 | 4.51 Mn |
| Sep 30, 2021 | 4.56 Mn |